You are here

Clinical Trials

REDUCE-IT Study Shows 25% Risk Reduction in CV Events with Vascepa
Two Phase 3 Studies Met Endpoint of Complete Clearance of Lesions
Claims that tramiprosate helps stabilize patients over an 18-month period.
Latest failure brings amyloid hypothesis into question
Phase 3 results showed significantly longer survival compared to chemotherapy alone
Product would be the first lotion to combine halobetasol and tazarotene in one formulation
Monotherapy significantly improved overall survival as first-line therapy in certain NSCLC patients
Study is ongoing to determine overall survival in patients with certain lung cancer
Treatment tested after bunionectomy and hernia repair surgery
Alexion announces positive top-line results for ALXN1210 in PNH
Sollpura didn’t meet noninferiority endpoint versus Pancreaze
Cardiovascular death, heart failure hospitalization decrease
Shorter course of therapy may increase patients’ treatment adherence
Lanadelumab reduced monthly attack rates and improved quality of life in study